You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

LP-184 Chemotherapy for Advanced Triple Negative Breast Cancer or Breast Cancer with DNA Damage Mutations

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of LP-184, an experimental chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer or breast cancer with a DNA damage mutation who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LP-184, by IV, weekly, 2 weeks on, 1 week off</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LP-184 is an experimental chemotherapy drug causing tumor cell death through DNA damage.</li> <li class="seamTextUnorderedListItem">DNA damage mutations may include BRCA1, BRCA2, PALB2, ATM, CHEK2, and others.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05933265' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lanternpharma.com/clinical-trials' target='_blank'>Lantern Pharma: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lanternpharma.com/compassionate-use#ExpandedAccessTNBC' target='_blank'>Lantern Pharma: LP-184 Compassionate Use for Triple Negative Breast Cancer</a> </li></ul>
1

LP-184 Chemotherapy for Advanced Triple Negative Breast Cancer or Breast Cancer with DNA Damage Mutations

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors
Icon

Nearest Location:
366 miles
Cancer and Blood Specialty Clinic
Los Alamitos, CA

Icon

Visits:
1 visit every 1-2 weeks

Icon

ClinicalTrials.gov: NCT05933265

Icon

Phase I-II

HELP GUIDE
HELP GUIDE